436
Views
10
CrossRef citations to date
0
Altmetric
Editorial

Innovative cancer drug targets: genomics, transcriptomics and clinomics

&
Pages 911-915 | Published online: 24 Feb 2005

Bibliography

  • SIKORA K, ADVANI S, KOROLTCHOUK V etal.: Essential drugs for cancer therapy: A World Health Organisation consultation. Ann. Oricol (1999) 10:385–390.
  • Cancer: Principles and Practice of Oncology (6th Edition). De Vita VT, Hellman S, Rosenberg SA (Eds.), Lippincott, Philadelphia, USA (2001).
  • HANAHAN D, WEINBERG A: The hallmarks of cancer. Cell (2000) 100:57–70.
  • GARRET MD, WORKMAN P: Millennium review. Discovering novel chemotherapeutic drugs for the third millennium. Eur. J. Cancer (1999) 35:2010–2030.
  • GIBBS JB: Mechanism-based target identification and drug discovery in cancer research. Science (2000) 287:1969–1973.
  • DREWS J: Genomic sciences and the medicine of tomorrow. Nature Biotech. (1996) 14:1518–1519
  • DREWS J: Drug discovery: A historical perspective. Science (2000) 287:1960–1964.
  • HORROBIN DF: Innovation in the pharmaceutical industry. _J. R. Soc. Med. (2000) 93:3412–3415.
  • BROWN P: Has R&D failed the pharmaceutical industry? Scrip Magazine. (1994) July/August:3–4.
  • SLAMON D, LEYLAND-JONES B, SHAK S etal.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastic breast cancer that overexpresses HER2. N Engl. j Med (2001) 344:783–792.
  • DRUKER BJ, TALPAZ M, REST DJ et atEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl. j Med. (2001) 344(14):1031–1037.
  • BASELGA J, AVERBUCH S D.:ZD1839 (Iressa') as an anticancer agent. Drugs (2000) 60:33-40 (Suppl. 1).
  • INTERNATIONAL HUMAN GENOME SEQUENCING CONSORTIUM: Initial sequencing and analysis of the human genome. Nature (2001) 409:860–921.
  • VENTER J C, ADAMS MD, MYERS EW et al.: The sequence of the human genome. Science (2001) 291:1304–1351.
  • EDITORIAL: The human genome, in proportion. Lancet (2001) 357:489
  • EDITORIAL: A cold dose of medicine. Nature Biotech. (2001) 19:181.
  • BALTIMORE D: Our genome unveiled. Nature (2001) 409:814–815.
  • CLAVERIE J-M: What if there are only 30,000 human genes? Science (2001) 291:1255–1257.
  • JIMINEZ-SANCHEZ G, CHILDS B, VALLE D: Human disease genes. Nature (2001) 409:853–855.
  • PALTONEN L, MCKUSICK VA: Dissecting human disease genes in the post genomic era. Science (2001) 291:1224–1229
  • DAVIES K: The sequence: Inside the racefor the human genome. London: Weidenfield and Nicolson, 2001. (Also published in the US under the title 'Cracking the Genome: Inside the race to unlock human DNA' by The Free Press).
  • THE INTERNATIONAL SNP MAP WORKING GROUP: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature (2001) 409:928–933.
  • RATAIN MJ, RELLING MV: Gazing intoa crystal ball - Cancer therapy in the post-genome era. Nature Med. (2001) 7:283–285.
  • LOCKHART DJ, WINZELAR EA: Genomics, gene expression and DNA arrays. Nature (2000) 405:827–836.
  • MURRAY AW, D MARKS: Can sequencing shed light on cell cycling? Nature (2001) 409:844–846.
  • FUTREAL PA, KSPRZYK A, BIRNEY E, MULLIKIN JC, WOOSTER R, STRATTON MR: Cancer and genomics. Nature (2001) 409:850–855.
  • WEINBERG RA: Oncogenes and the molecular origins of cancer. Cold Spring Harbor Press (1989).
  • VOGELSTEIN B, KINZLER K: The multistep nature of cancer. Trends Genet. (1993) 9:138–141.
  • HAHN WC, COUNTER CM, LUNDBERG AS, BIJERSBERGEN RL, BROOKS MW, WEINBERG RA: Creation of human tumour cells with defined genetic elements. Nature (1999) 400:464–468.
  • PEROU CM, SERLIE T, EISEN MB oral.: Molecular portraits of human breast tumours. Nature (2000) 406:747–752.
  • GOLUB TR, SLONIM DK, TAMAYO P et al.: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 286:531–537.
  • DEBOUCK C, GOODFELLOW PN: DNA microarrays in drug discovery and development. Nature Genet. (1999) 21:48–51.
  • STRATOWA C, WILGENBUS KK: Gene expression profiling in drug discovery. Curr. Opin. Mol. Ther. (1999) 1:671–679.
  • CLARKE PA, TE POELE R, WOOSTER R, WORKMAN P: Gene expression microarray analysis in cancer biology, pharmacology and drug development: Progress and potential. Biochern. Phannacol. (2001) (In Press).
  • SCHERF U, ROSS DT, WALTHAM M et al.: A gene expression database for the molecular pharmacology of cancer. Nature Genetics (2000) 24:227–235.
  • CLARKE PA, HOSTEIN I, BANERJI U etaL:Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxy geldanamycin, an inhibitor of the Hsp90 molecular chaperone. Oricogerre (2000) 19:4125–4133.
  • EDITORIAL: All hands on deck at dawn. Nature Genetics (2001) 27:347–349.
  • KELLAND LR, SHARP SY, ROGERS PM, MYERS TG, WORKMAN P: Dt-diaphorase expression and tumour cell sensitivity to 17-allylamino,17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Nati Can. Inst. (1999) 91(22):1940–1949.
  • HOSTEIN I, ROBERTSON D, DI STEFANO F, WORKMAN P, CLARKE PA: Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino - 17 demethoxy geldanamylin results in cytostasis and apoptosis. Cancer Res. (2001). (In Press).
  • PARIS M: Vapornomics. Nature Biotech. (2001) 19:301.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.